Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 74.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,601 shares of the company’s stock after acquiring an additional 3,667 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Mirum Pharmaceuticals were worth $254,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in MIRM. Commonwealth Equity Services LLC bought a new position in shares of Mirum Pharmaceuticals in the third quarter worth $379,000. Raymond James & Associates grew its position in Mirum Pharmaceuticals by 57.1% in the 3rd quarter. Raymond James & Associates now owns 106,207 shares of the company’s stock valued at $3,356,000 after buying an additional 38,619 shares in the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Mirum Pharmaceuticals by 31.2% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 49,891 shares of the company’s stock valued at $1,577,000 after buying an additional 11,862 shares during the period. Bank of New York Mellon Corp raised its position in shares of Mirum Pharmaceuticals by 5.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 118,051 shares of the company’s stock worth $3,730,000 after buying an additional 5,861 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Mirum Pharmaceuticals by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,106 shares of the company’s stock worth $541,000 after acquiring an additional 3,069 shares during the period.

Analyst Ratings Changes

A number of research firms recently commented on MIRM. Cantor Fitzgerald reiterated an “overweight” rating and set a $35.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. HC Wainwright reiterated a “buy” rating and set a $58.00 price target on shares of Mirum Pharmaceuticals in a research report on Tuesday, April 2nd. Stifel Nicolaus began coverage on Mirum Pharmaceuticals in a report on Wednesday, April 17th. They issued a “buy” rating and a $48.00 price objective for the company. SVB Leerink lowered their target price on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a report on Monday, March 18th. Finally, JMP Securities upped their price target on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $51.70.

Mirum Pharmaceuticals Trading Up 2.1 %

Shares of MIRM opened at $26.39 on Tuesday. The business’s 50-day moving average price is $26.06 and its 200 day moving average price is $28.17. The company has a current ratio of 4.45, a quick ratio of 4.19 and a debt-to-equity ratio of 1.23. The stock has a market capitalization of $1.24 billion, a P/E ratio of -6.65 and a beta of 1.13. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $35.56.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 66.24% and a negative net margin of 86.33%. The firm had revenue of $69.55 million during the quarter, compared to analysts’ expectations of $66.73 million. Analysts expect that Mirum Pharmaceuticals, Inc. will post -1.34 earnings per share for the current year.

Insiders Place Their Bets

In other news, COO Peter Radovich sold 4,303 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the sale, the chief operating officer now owns 29,013 shares in the company, valued at $748,535.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt bought 2,000 shares of the stock in a transaction on Wednesday, March 27th. The shares were bought at an average price of $24.80 per share, with a total value of $49,600.00. Following the purchase, the chief financial officer now directly owns 14,000 shares in the company, valued at approximately $347,200. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Peter Radovich sold 4,303 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the completion of the transaction, the chief operating officer now owns 29,013 shares in the company, valued at approximately $748,535.40. The disclosure for this sale can be found here. Corporate insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.